Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
about
The role of PARP in DNA repair and its therapeutic exploitationPARP inhibition: PARP1 and beyondRationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.Poly(ADP-ribose) polymerase-1 inhibition: preclinical and clinical development of synthetic lethality.Discordant in vitro and in vivo chemopotentiating effects of the PARP inhibitor veliparib in temozolomide-sensitive versus -resistant glioblastoma multiforme xenografts.Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitorsEfficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.BRCA1 Mutation: A Predictive Marker for Radiation Therapy?An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair.Predicting enhanced cell killing through PARP inhibition.Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in VivoTherapeutic applications of PARP inhibitors: anticancer therapy and beyondReplication-dependent irreversible topoisomerase 1 poisoning is responsible for FdUMP[10] anti-leukemic activityPoly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastomaInhibiting the DNA damage response as a therapeutic manoeuvre in cancer.Strategic Combination of DNA-Damaging Agent and PARP Inhibitor Results in Enhanced CytotoxicityPreclinical evaluation of the PARP inhibitor, olaparib, in combination with cytotoxic chemotherapy in pediatric solid tumors.Small-molecule inhibitors of proteins involved in base excision repair potentiate the anti-tumorigenic effect of existing chemotherapeutics and irradiation.Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly(ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo?A review of PARP inhibitors: from bench to bedside.The clinical development of inhibitors of poly(ADP-ribose) polymerase.Therapeutic intervention by the simultaneous inhibition of DNA repair and type I or type II DNA topoisomerases: one strategy, many outcomes.Predictive biomarkers for cancer therapy with PARP inhibitors.Poly(ADP-ribose) polymerase inhibitors in Ewing sarcoma.The potential of PARP inhibitors in neuro-oncology.NF-κB mediates radio-sensitization by the PARP-1 inhibitor, AG-014699.PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma.Temozolomide may induce cell cycle arrest by interacting with URG4/URGCP in SH-SY5Y neuroblastoma cells.Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.The development of PARP as a successful target for cancer therapy.The Shc protein RAI promotes an adaptive cell survival program in hypoxic neuroblastoma cells.Sensitizing Ewing sarcoma to chemo- and radiotherapy by inhibition of the DNA-repair enzymes DNA protein kinase (DNA-PK) and poly-ADP-ribose polymerase (PARP) 1/2.
P2860
Q27002399-DB264B31-F0D5-4A0E-BF81-B6EE8132CF24Q29619617-922ED67A-6C24-48A2-BD78-6C63D7D3BC5AQ33603605-FD933753-A474-4D07-949C-3F73401CA7A2Q33729396-6BEC534D-DEFA-4C8E-AA56-E06B786BAAD4Q33851843-A5376C6C-5947-40D7-9EAC-721DEA79102EQ33953822-24595EA6-B9B0-490E-97B0-4F0AEBC8952EQ35142790-E7BE86CC-5B31-4D51-9D4B-1A1051E03025Q35799917-598855B6-2905-4CFF-8B55-17C661EA8698Q36076772-4C1A1EEA-6FEE-4D4E-88F7-21EE11572D36Q36102008-C26AFA42-422B-4566-83E3-9F26379EAC1FQ36280791-D184DB28-499C-4C9A-B53E-BFD3E635B431Q36553266-F4875DD2-5D38-42C1-9BF2-252A27568BCAQ36743450-FEAAE498-61C8-4910-91D2-39B4B21C1471Q36853236-47CD3776-C9D2-49FD-8B85-E28218239479Q36862902-A45B05EC-66A8-4D65-971D-0DE87F518018Q36934727-F95212C2-4A3B-46CE-A2B5-177539420156Q37122690-1D0ED542-9784-4E13-AF8D-828EF1F4BF7FQ37205681-5F80738A-F7DD-4D88-9820-3007AE971C61Q37362118-B8EB08B0-1CA9-4304-9D62-50B86100328AQ37372941-6481FCC3-1BB7-4952-860E-E24C616A6E0EQ37373632-8D2564CA-7C92-4EB6-87FE-E91869E128BFQ37774151-84C92DB2-024E-49DF-90FA-95FA57B5A17CQ37834139-465C4617-BC54-4F47-8D21-E1C1D40B4255Q37968253-442C13F6-DA97-449F-ACB1-91387A44032EQ38137764-F3CEEC31-DC14-42F6-A644-D8CE763C32A4Q38212771-7390B6C0-E222-4BAD-86B3-740C1353607FQ38233068-ED5D47A2-B9B2-4A85-BD5A-D8CB75A56080Q38677373-AA5F3AB9-F2A9-485C-B712-ADA2FD287E8BQ38844568-9D7BEBB0-D800-4CFF-AFA3-6F8EF5B75EB5Q38891614-04170100-296C-4CF0-9254-5176718C73BCQ41871248-3AB29394-E2A8-4EF0-946F-659BD24B80FCQ47278103-FA5545C4-0826-420E-AEC2-599AA784F4A8Q47618719-1F803710-D270-46C5-B15E-4ACCECCFAD9BQ47710977-CFFCFFDE-5282-4741-8393-A3E2B204D173
P2860
Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.
@ast
Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.
@en
type
label
Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.
@ast
Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.
@en
prefLabel
Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.
@ast
Inhibition of poly(ADP-ribose) ...... ainst childhood neuroblastoma.
@en
P2093
P1476
Inhibition of poly(ADP-ribose) ...... gainst childhood neuroblastoma
@en
P2093
Agata L Rozanska
Deborah A Tweddle
Deborah J Castelbuono
E Ruth Plummer
Evan A Mulligan
Huw D Thomas
Rachel A Daniel
Steven C Clifford
Yvette Drew
Zdenek Hostomsky
P304
P356
10.1158/1078-0432.CCR-08-1095
P407
P577
2009-01-27T00:00:00Z